Abstract
Purpose: Atezolizumab, an immunoglobulin G1 monoclonal antibody against PD-L1, is accepted to treat advanced non-small-cell lung cancer (NSCLC). Our s......
小提示：本篇文献需要登录阅读全文，点击跳转登录
Full Text Link
